Literature DB >> 12210500

Determination of allelic deletion of multiple endocrine neoplasm type 1 (MEN1) gene in acute myeloid leukemia (AML) by application of FISH-TSA technique.

Hasan Acar1, Murat Kaynak, Tahsin Yakut, Fahri Uçar, Unal Egeli.   

Abstract

We have used the single and dual color fluorescence in situ hybridization (FISH) technique combined with a new detection system, tyramide signal amplification (TSA), by using the multiple endocrine neoplasm type 1 (MEN1) gene and chromosome 11 specific alpha satellite DNA probes for the study of the allelic deletion of the MEN1 gene. The MEN1 gene is a new tumor suppressor gene and has been recently cloned on chromosome 11q13. FISH combined with the TSA detection system was performed on bone marrow interphase nuclei of 22 patients with acute myeloid leukemia (AML). The FISH-TSA analysis revealed the mono allelic deletion of the MEN1 gene in 4 out of 22 patients (18.18%), 2 of 9 AML-M2 patients (22.2%), 1 of 6 AML-M4 patients (16.6%), and 1 of 4 AML-M5 patients (25.0%). Our study indicates that allelic deletion of the MEN1 gene is not a major cause or a primary event in tumorigenesis of AML, although the long arm (q13 region) of chromosome 11 involves a chromosomal rearrangement in AML. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210500     DOI: 10.1002/tcm.10033

Source DB:  PubMed          Journal:  Teratog Carcinog Mutagen        ISSN: 0270-3211


  2 in total

1.  Ph1-positive acute lymphoblastic leukemia in a patient with a germline MEN1 gene mutation.

Authors:  Naoaki Ichikawa; Hikaru Kobayashi; Hiroshi Saito
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

2.  Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically-defined cell populations for gated genotyping.

Authors:  Raymond R Tubbs; Kingshuk Das; James R Cook; James D Pettay; Patrick C Roche; Thomas Grogan
Journal:  J Mol Histol       Date:  2007-01-05       Impact factor: 3.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.